Cargando…
Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities
Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberra...
Autores principales: | Yu, Eun-mi, Hwang, Min Woo, Aragon-Ching, Jeanny B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693764/ https://www.ncbi.nlm.nih.gov/pubmed/38050587 http://dx.doi.org/10.2147/RRU.S386517 |
Ejemplares similares
-
ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
por: Aragon-Ching, Jeanny B
Publicado: (2022) -
Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014) -
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate
Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016) -
The path forward in prostate cancer therapeutics
por: Aragon-Ching, Jeanny B, et al.
Publicado: (2018) -
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)